{"id":958339,"date":"2026-05-05T14:10:03","date_gmt":"2026-05-05T18:10:03","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/"},"modified":"2026-05-05T14:10:03","modified_gmt":"2026-05-05T18:10:03","slug":"apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/","title":{"rendered":"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program"},"content":{"rendered":"

<\/p>\n

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program<\/b><\/p>\n

Trading Expected to Resume on NYSE American on Tuesday, May 5<\/i><\/b><\/p>\n

MATAWAN, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE<\/a>)–
\nApimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the \u201cInscobee Parties\u201d), resolving all outstanding disputes arising from the APUS\u2019 December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company\u2019s previously disclosed $100 million PIPE financing, and the advancement of L\u014dkahi Therapeutics, Inc. as an independent biopharmaceutical company focused on the Apitox program.<\/p>\n

\nAPUS\u2019 common stock is expected to resume trading on the NYSE American on Tuesday, May 5, 2026, subject to NYSE approval.<\/p>\n

Aligned governance. <\/b>The Inscobee parties have confirmed that the Stockholder Support and Lock-Up Agreement and related voting agreements remain valid and binding, and that prior purported written stockholder consents to remove the Company\u2019s directors are void. Dr. Vin Menon continues to serve as Co-Chief Executive Officer, along with Co-Chief Executive Officer Sungjoon Chae, leading the Newco subsidiary discussed below. The Inscobee parties have granted an irrevocable proxy to vote in favor of the proposals outlined in the Company\u2019s February 27, 2026, Information Statement on Schedule 14C, including the conversion of the Series A Convertible Preferred Stock and outstanding convertible notes and the previously disclosed 1-for-10 reverse stock split.<\/p>\n

L\u014dkahi to advance the Apitox program. <\/b>L\u014dkahi, securing the rights relating to the Apitox program, including all relevant intellectual property, regulatory materials, development data, manufacturing information, and all other associated program assets, will deliver $4 million to APUS within five business days following the effective date of the settlement. APUS will also assign to L\u014dkahi the $2.2 million Prevail CRO credit facility to support continued development of the Apitox program. Following payment, APUS will distribute 51% of the common stock of L\u014dkahi as directed by Erik Emerson, the Company\u2019s former Chief Executive Officer, with the Company retaining the remaining 49%.<\/p>\n

Newco formation. <\/b>The settlement provides for the formation of a new wholly owned subsidiary of the Company (\u201cNewco\u201d) within seven business days of the effective date. Ten percent of the net proceeds from APUS\u2019 financing arrangement will be allocated to Newco, with the remaining ninety percent allocated to MindWave. Newco is expected to be spun off from the Company within twelve months.<\/p>\n

About Apimeds Pharmaceuticals US, Inc.<\/b><\/p>\n

\nApimeds Pharmaceuticals US, Inc. (NYSE American: APUS) is a clinical-stage biopharmaceutical company focused on developing non-opioid, biologic-based therapies for pain management. For more information, visit www.apimedsus.com<\/a>.<\/p>\n

About MindWave Innovations Inc.<\/b><\/p>\n

\nMindWave Innovations Inc is a leading provider of institutional Digital Asset Treasury (DAT) solutions, specializing in compliance Bitcoin treasury infrastructure, AI-driven yield capabilities, ClimateTech impact systems, and AdTech engagement platforms. The company\u2019s multi-vertical ecosystem is powered by its native token, $NILA, which enables governance, utility, and value flow across its blockchain-integrated operations. For more information, visit www.mindwavedao.com<\/a>.<\/p>\n

About L\u014dkahi Therapeutics<\/b><\/p>\n

\nL\u014dkahi Therapeutics is focused on advancing innovative therapeutic opportunities through disciplined evaluation, strategic development, and collaborative discovery. Through initiatives like the ai\u00b2 Futures Lab, L\u014dkahi integrates emerging talent into real-world problem-solving to help shape the future of healthcare. For more information, visit www.lokahithera.com<\/a>.<\/p>\n

Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as \u201canticipate\u201d, \u201cbelieve\u201d, \u201cexpect\u201d, \u201cplan\u201d, and \u201cwill\u201d are intended to identify forward-looking statements. Such forward-looking statements are based on the beliefs of management, as well as assumptions made by, and information currently available to, management. These statements relate only to events as of the date on which the statements are made, and Apimeds undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. All of the forward-looking statements made in this press release are qualified by these cautionary statements, and there can be no assurance that the actual results anticipated by Apimeds will be realized or, even if substantially realized, that they will have the expected consequences to or effects on the company or its business or operations. Readers are cautioned that certain important factors may affect Apimeds\u2019 actual results and could cause such results to differ materially from any forward-looking statements that may be made in this press release. Factors that may affect Apimeds\u2019 results include, but are not limited to, the ability of Apimeds to raise additional capital to finance its operations (whether through public or private equity offerings, debt financings, strategic collaborations or otherwise); risks relating to Apimeds\u2019 ability to advance its product candidate and successfully complete clinical trials; risks relating to its ability to hire and retain qualified personnel; and the additional risk factors described in Apimeds\u2019 filings with the U.S. Securities and Exchange Commission (the \u201cSEC\u201d), including its Annual Report on Form 10-K for the year ended December 31, 2025 as filed with the SEC on May 4, 2026.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20260505841532\/en\/<\/a><\/span><\/p>\n

Media Contact:
\n<\/b>
Dr. Vin Menon
\n
ceo@mindwavedao.com<\/a><\/p>\n

KEYWORDS:<\/b> California New Jersey United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Legal Research Health Technology Professional Services Biotechnology Health Pharmaceutical General Health Science<\/p>\n

MEDIA:<\/b><\/p>\n\n","protected":false},"excerpt":{"rendered":"

Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program Trading Expected to Resume on NYSE American on Tuesday, May 5 MATAWAN, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)– Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the \u201cInscobee Parties\u201d), resolving all outstanding disputes arising from the APUS\u2019 December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company\u2019s previously disclosed $100 million PIPE financing, and the advancement of L\u014dkahi Therapeutics, Inc. as an independent biopharmaceutical company focused on the Apitox program. APUS\u2019 common stock is expected to … <\/p>\n

Continue reading “Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-958339","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nApimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program Trading Expected to Resume on NYSE American on Tuesday, May 5 MATAWAN, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)– Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the \u201cInscobee Parties\u201d), resolving all outstanding disputes arising from the APUS\u2019 December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company\u2019s previously disclosed $100 million PIPE financing, and the advancement of L\u014dkahi Therapeutics, Inc. as an independent biopharmaceutical company focused on the Apitox program. APUS\u2019 common stock is expected to … Continue reading "Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-05T18:10:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260505841532r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program\",\"datePublished\":\"2026-05-05T18:10:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/\"},\"wordCount\":933,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260505841532r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/\",\"name\":\"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260505841532r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2026-05-05T18:10:03+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260505841532r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20260505841532r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/","og_locale":"en_US","og_type":"article","og_title":"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program - Market Newsdesk","og_description":"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program Trading Expected to Resume on NYSE American on Tuesday, May 5 MATAWAN, N.J. & LA JOLLA, Calif.–(BUSINESS WIRE)– Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) today announced a comprehensive settlement with Inscobee Inc. and Apimeds Inc. (the \u201cInscobee Parties\u201d), resolving all outstanding disputes arising from the APUS\u2019 December 1, 2025, merger with MindWave Innovations Inc. The settlement clears the path for completion of the merger transactions, effectuation of the Company\u2019s previously disclosed $100 million PIPE financing, and the advancement of L\u014dkahi Therapeutics, Inc. as an independent biopharmaceutical company focused on the Apitox program. APUS\u2019 common stock is expected to … Continue reading \"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/","og_site_name":"Market Newsdesk","article_published_time":"2026-05-05T18:10:03+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260505841532r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program","datePublished":"2026-05-05T18:10:03+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/"},"wordCount":933,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260505841532r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/","name":"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260505841532r1&sid=flmnd&distro=nx&lang=en","datePublished":"2026-05-05T18:10:03+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260505841532r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20260505841532r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/apimeds-pharmaceuticals-us-settles-with-inscobee-merger-proceeds-100-million-pipe-financing-to-close-and-lokahi-therapeutics-to-advance-apitox-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Apimeds Pharmaceuticals US Settles with Inscobee; Merger Proceeds, $100 Million PIPE Financing to Close, and L\u014dkahi Therapeutics to Advance Apitox Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958339","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=958339"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/958339\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=958339"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=958339"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=958339"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}